Schizophrenia risk genes: Implications for future drug development and discovery [Review]

O'Connell, Garret, Lawrie, Stephen M., McIntosh, Andrew M. and Hall, Jeremy ORCID: https://orcid.org/0000-0003-2737-9009 2011. Schizophrenia risk genes: Implications for future drug development and discovery [Review]. Biochemical Pharmacology 81 (12) , pp. 1367-1373. 10.1016/j.bcp.2010.11.009

Full text not available from this repository.

Abstract

Present-day development of improved treatments for schizophrenia is hindered by uncertain models of disease, inter-individual response variability in clinical trials and a paucity of sensitive measures of treatment effects. Findings from genetic research emphasize the potential for schizophrenia risk genes to help develop focused treatments, discover new drug targets and provide markers of clinical subtypes. Advances in genetic technologies also provide novel modes of drug discovery in schizophrenia such as transcriptomics, epigenetics and transgenic animal models. In this review, we discuss proven and proposed ways risk genes can be used to enhance the development and discovery of treatments for schizophrenia and highlight key studies in these approaches.

Item Type:	Article
Date Type:	Publication
Status:	Published
Schools:	Medicine
Subjects:	R Medicine > R Medicine (General)
Publisher:	Elsevier
ISSN:	0006-2952
Last Modified:	31 Oct 2022 09:18
URI:	https://orca.cardiff.ac.uk/id/eprint/80509

Citation Data

Cited 10 times in Scopus. View in Scopus. Powered By Scopus® Data

Actions (repository staff only)

Edit Item